Allogeneic hematopoietic cell transplant in HCV-infected patients

[Guest guest]

J Hepatol. 2008 Apr 1 [Epub ahead of print]

Allogeneic hematopoietic cell transplant in HCV-infected patients.

Peffault de Latour R, Ribaud P, Robin M, Valla D, Marcellin P, Socié G, Asselah

T.

Service d’Hématologie-Greffe, Hôpital Saint Louis, 75475 Paris, France.

Hepatitis C virus (HCV) is a major cause of liver disease worldwide. After

allogeneic Hematopoietic Cell Transplant (HCT), HCV is known to be associated

with transient hepatitis in the immediate post-transplant period, and a

potential risk factor of veno-occlusive disease (SOS). Very recently,

HCV-infected HCT recipients have been shown to be at higher risk of earlier

cirrhosis, leading to greater morbidity and mortality. Long-term survivors after

HCT are thus at a high risk for HCV-related complications and, as a consequence,

the treatment of HCV infection becomes critical. We describe here the potential

clinical complications in HCV-infected recipients, in the short, but also the

long-term follow-up after HCT. The pathophysiology of liver fibrosis is

discussed as well as the present recommended therapy in this particular

population.

PMID: 18433917 [PubMed - as supplied by publisher]

_________________________________________________________________

Back to work after baby–how do you know when you’re ready?

http://lifestyle.msn.com/familyandparenting/articleNW.aspx?cp-documentid=5797498\

& ocid=T067MSN40A0701A